Brief: Final Data Confirm Positive Phase 1b Results With Alzinova's ALZ-101 Against Alzheimer's Disease
27/03/2025 08:50
March 27 (Reuters) - Alzinova AB ALZ.ST: PHASE 1B STUDY ACHIEVES PRIMARY AND SECONDARY OBJECTIVES ALZ-101 SHOWN TO BE SAFE AND TOLERABLE IN PHASE 1B TRIAL EXPLORATORY ENDPOINTS SHOW STABLE DISEASE PICTURE WITH NO DETERIORATION CEO: STUDY RESULTS EXCEEDED EXPECTATIONS CEO: ALTHOUGH IT WAS DESIGNED TO EVALUATE THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF ALZ-101, WE ARE ALREADY SEEING CLEAR TRENDS SUGGESTING A CLINICALLY MEANINGFUL TREATMENT EFFECT Source text: ID:nMFN30vZNy Further company coverage: ALZ.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))